Summary
MASSIVE falls hit shares in Elan yesterday after a new case of brain swelling was confirmed in a patient using its flagship multiple sclerosis drug Tysabri.
The company's shares tumbled initially by nearly 50pc in the U.S. after news of the patient contracting progressive multifocal leukoencephalopathy (PML) was released.See the full content of this document
Extract
Elan Hit by New Drug Concerns
Although the U.S. price had recovered substantially by yesterday morning, the roller coaster continued on...
See the full content of this document
Sponsored links
